Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients.
Mingot-Castellano ME, Reguera-Ortega JL, Zafra Torres D, Hernani R, Lopez-Godino O, Guerreiro M, Herrero B, López-Corral L, Luna A, Gonzalez-Pinedo L, Chinea-Rodriguez A, Africa-Martín A, Bailen R, Martinez-Cibrian N, Balsalobre P, Filaferro S, Alonso-Saladrigues A, Barba P, Perez-Martinez A, Calbacho M, Perez-Simón JA, Sánchez-Pina JM, On Behalf Of The Spanish Group Of Hematopoietic Transplant And Cell Therapy Geth-Tc. Mingot-Castellano ME, et al. Among authors: reguera ortega jl. J Clin Med. 2024 Aug 28;13(17):5117. doi: 10.3390/jcm13175117. J Clin Med. 2024. PMID: 39274330 Free PMC article.
Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features.
Sierro-Martínez B, Escamilla-Gómez V, Pérez-Ortega L, Guijarro-Albaladejo B, Hernández-Díaz P, de la Rosa-Garrido M, Lara-Chica M, Rodríguez-Gil A, Reguera-Ortega JL, Sanoja-Flores L, Arribas-Arribas B, Montiel-Aguilera MÁ, Carmona G, Robles MJ, Caballero-Velázquez T, Briones J, Einsele H, Hudecek M, Pérez-Simón JA, García-Guerrero E. Sierro-Martínez B, et al. Among authors: reguera ortega jl. Cell Oncol (Dordr). 2024 Aug 27. doi: 10.1007/s13402-024-00984-0. Online ahead of print. Cell Oncol (Dordr). 2024. PMID: 39192092
Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO.
Bailén R, Iacoboni G, Delgado J, López-Corral L, Hernani-Morales R, Ortiz-Maldonado V, Guerreiro M, Caballero AC, Guerra-Domínguez ML, Sánchez-Pina JM, Peña M, Torrent A, Pérez-Martínez A, Bastos-Oreiro M, Reguera-Ortega JL, Martín A, Hernandez-Boluda JC, Martínez-Cibrián N, Sanz J, Briones J, Henriquez HL, Calbacho M, Mussetti A, Sancho JM, Barba P, Kwon M; GETH-TC (Spanish Group of Stem Cell Transplantation and Cell Therapy) and GELTAMO (Spanish Group of Lymphoma and Autologous Stem Cell Transplantation). Bailén R, et al. Among authors: reguera ortega jl. Transplant Cell Ther. 2024 Jul 26:S2666-6367(24)00485-8. doi: 10.1016/j.jtct.2024.06.022. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39069076
Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, Jäger U, Cartron G, Izutsu K, Dreyling M, Kahl B, Ghesquieres H, Ardeshna K, Goto H, Barbui AM, Abramson JS, Borchmann P, Fleury I, Mielke S, Skarbnik A, de Vos S, Kamdar M, Karmali R, Viardot A, Farazi T, Fasan O, Lymp J, Vedal M, Nishii R, Avilion A, Papuga J, Kumar J, Nastoupil LJ. Morschhauser F, et al. Among authors: reguera ortega jl. Nat Med. 2024 Aug;30(8):2374. doi: 10.1038/s41591-024-03175-4. Nat Med. 2024. PMID: 38982297 Free PMC article. No abstract available.
Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells.
Iacoboni G, Sánchez-Salinas MA, Rejeski K, Martín-López AÁ, Kwon M, Navarro V, Jalowiec KA, Hernani R, Reguera-Ortega JL, Gallur L, Blumenberg V, Herrero-García M, Roddie C, Benzaquén A, Delgado-Serrano J, Bailén R, Carpio C, Amat P, López-Corral L, Martín-Martín L, Bastos M, Subklewe M, O'Reilly M, Barba P. Iacoboni G, et al. Among authors: reguera ortega jl. Hemasphere. 2024 Jun 26;8(7):e86. doi: 10.1002/hem3.86. eCollection 2024 Jul. Hemasphere. 2024. PMID: 38948924 Free PMC article.
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, Jäger U, Cartron G, Izutsu K, Dreyling M, Kahl B, Ghesquieres H, Ardeshna K, Goto H, Barbui AM, Abramson JS, Borchmann P, Fleury I, Mielke S, Skarbnik A, de Vos S, Kamdar M, Karmali R, Viardot A, Farazi T, Fasan O, Lymp J, Vedal M, Nishii R, Avilion A, Papuga J, Kumar J, Nastoupil LJ. Morschhauser F, et al. Among authors: reguera ortega jl. Nat Med. 2024 Aug;30(8):2199-2207. doi: 10.1038/s41591-024-02986-9. Epub 2024 Jun 3. Nat Med. 2024. PMID: 38830991 Free PMC article. Clinical Trial.
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
Iacoboni G, Navarro V, Martín-López AÁ, Rejeski K, Kwon M, Jalowiec KA, Amat P, Reguera-Ortega JL, Gallur L, Blumenberg V, Gutiérrez-Herrero S, Roddie C, Benzaquén A, Delgado-Serrano J, Sánchez-Salinas MA, Bailén R, Carpio C, López-Corral L, Hernani R, Bastos M, O'Reilly M, Martín-Martín L, Subklewe M, Barba P. Iacoboni G, et al. Among authors: reguera ortega jl. J Clin Oncol. 2024 Jan 10;42(2):205-217. doi: 10.1200/JCO.23.01097. Epub 2023 Oct 24. J Clin Oncol. 2024. PMID: 37874957
Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review.
Pérez-Moreno MA, Ciudad-Gutiérrez P, Jaramillo-Ruiz D, Reguera-Ortega JL, Abdel-Kader Martín L, Flores-Moreno S. Pérez-Moreno MA, et al. Among authors: reguera ortega jl. Int J Mol Sci. 2023 Sep 30;24(19):14780. doi: 10.3390/ijms241914780. Int J Mol Sci. 2023. PMID: 37834228 Free PMC article. Review.
Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies.
García-Calderón CB, Sierro-Martínez B, García-Guerrero E, Sanoja-Flores L, Muñoz-García R, Ruiz-Maldonado V, Jimenez-Leon MR, Delgado-Serrano J, Molinos-Quintana Á, Guijarro-Albaladejo B, Carrasco-Brocal I, Lucena JM, García-Lozano JR, Blázquez-Goñi C, Reguera-Ortega JL, González-Escribano MF, Reinoso-Segura M, Briones J, Pérez-Simón JA, Caballero-Velázquez T. García-Calderón CB, et al. Among authors: reguera ortega jl. Front Immunol. 2023 Apr 14;14:1152498. doi: 10.3389/fimmu.2023.1152498. eCollection 2023. Front Immunol. 2023. PMID: 37122702 Free PMC article.
Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib.
Rodríguez-Gil A, Escamilla-Gómez V, Nufer M, Andújar-Sánchez F, Lopes-Ramos T, Bejarano-García JA, García-Guerrero E, Calderón-Cabrera C, Caballero-Velázquez T, García-Calderón CB, Hernández-Díaz P, Reguera-Ortega JL, Rodríguez-Torres N, Martínez-Cibrián N, Rodríguez-Barbosa JI, Villadiego J, Pérez-Simón JA. Rodríguez-Gil A, et al. Among authors: reguera ortega jl. Sci Rep. 2022 May 19;12(1):8348. doi: 10.1038/s41598-022-12407-x. Sci Rep. 2022. PMID: 35589917 Free PMC article.
14 results